Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval

Merck (MRK) announced that the FDA had granted approval to V116, its 21-valent pneumococcal conjugate vaccine (PCV), for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. For the prevention of pneumonia indication, the FDA granted accelerated approval.The vaccine will be marketed by the trade name of Capvaxive. Capvaxive becomes the first PCV specifically designed for adults to be approved by the FDA. Capvaxive targets serotypes that account for approximately 84% of all i ...